Renin-angiotensin-aldosterone system inhibitors, including angiotensin converting enzyme inhibitors and angiotensin receptor blockers, are first-line therapies due to their benefits in reducing proteinuria and slowing CKD progression.[28] However, treatment resistance is common in CKD, requiring combination therapies and personalized approaches. Here, REN is linked to chronic kidney disease.